Elite Pharmaceuticals ELTP
OTC ELTP
$0.37 +0.05 (+14.06%)
As of: Nov 16, 2026 · 12:26 PM EST

Elite Pharmaceuticals (ELTP) Convertible Debt (2013)

Updated

Elite Pharmaceuticals' Convertible Debt was $6.07 million in fiscal Q3 2014 (quarter ended Dec 31, 2013).

Analysis

Elite Pharmaceuticals (ELTP) Convertible Debt (2013) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,291.18 Bn 1,264.79 Bn 20.46 Bn
2 Johnson & Johnson 686.56 Bn 606.42 Bn 17.30 Bn
3 AbbVie 525.29 Bn 493.30 Bn 13.12 Bn
4 Merck 362.24 Bn 325.18 Bn 13.19 Bn
5 Novartis Ag 313.66 Bn 286.90 Bn -
6 Astrazeneca 286.68 Bn 260.20 Bn 13.26 Bn
7 Amgen 253.44 Bn 205.10 Bn 7.58 Bn
8 Gilead Sciences 210.62 Bn 185.73 Bn 6.73 Bn
9 Pfizer 165.41 Bn 112.77 Bn 12.56 Bn
10 Elite Pharmaceuticals 397.46 Mn 270.87 Mn 15.99 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2013 6.07 Mn
API Access

Elite Pharmaceuticals Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=ELTP&period=max&api_key=YOUR_API_KEY